For BARD1, MSH2, MLH1, MSH6, PMS2, EPCAM, BRIP1, RAD51C, and RAD51D, there are some data, suggesting an elevated lifetime risk of breast cancer; however, there is insufficient evidence to support change in breast cancer risk management based on the presence of a mutation alone. Here, MSH2 is linked to breast carcinoma.